Riabni Injection, Solution
Product Images NDC 55513-326

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Riabni (NDC 55513-326). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amgen, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Riabni 01)

A Kaplan-Meier curve chart showing progression-free survival probability over time in months for two treatment groups: Observation and Rituximab. The Y-axis represents progression-free survival probability from 0 to 1.0, and the X-axis shows time in months up to 42. The chart includes number at risk tables for both groups at various time points, with Observation displayed as a solid red line and Rituximab as a dashed blue line.*

FDA Label Image

Figure 2 (Riabni 02)

A line chart showing the percentage of ACR 20 responders over 24 weeks for two groups: placebo and Rituximab 2x1000mg. The x-axis represents weeks from 0 to 24, and the y-axis represents the percent of responders from 0 to 100%. The Rituximab group shows a higher and sustained response rate compared to the placebo group throughout the timeline.*

FDA Label Image

Principal Display Panel (100 mg/10 mL Vial Label)

A Kaplan-Meier survival curve chart comparing the percentage of patients with first major relapse over time in months between two treatments: Azathioprine (red dashed line) and Rituximab (blue solid line). The chart includes tables below showing the number of subjects with major relapse and subjects at risk for each treatment at various time points up to 28 months.*

FDA Label Image

Principal Display Panel (500 mg/50 mL Vial Label)

Label for Riabni (rituximab-arrx) injection, 100 mg per 10 mL solution for intravenous infusion. The label notes the product as a single-dose vial from Amgen, Inc., with storage instructions to keep refrigerated between 2°C to 8°C (36°F to 46°F), protect from sunlight, and avoid freezing or shaking. It states the solution is sterile with no preservative and emphasizes the requirement of an enclosed medication guide for each patient.*

FDA Label Image

Riabni 05

Riabni 500 mg/50 mL injection, solution for intravenous use, in a single-dose vial. The label shows the proprietary name Riabni and its generic name rituximab-arrx. It is manufactured by Amgen, Inc. The label includes storage instructions and notes that it is a sterile solution with no preservative.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.